Mednet Logo
HomeEndocrinology
Endocrinology

Endocrinology

Physician discussions on diabetes management, thyroid disorders, hormonal imbalances, and metabolic conditions.

Recent Discussions

What are the advantages of oral octreotide acetate over its long acting injectable formulation for treatment of acromegaly?

1
1 Answers

Mednet Member
Mednet Member
Endocrinology · Johns Hopkins Endocrinology and Pituitary Center

Oral octreotide has been associated with improved patient-reported QoL measures compared with those reported for injectable lanreotide and octreotide, and a lower incidence of breakthrough symptoms. However, not all patients who are controlled by injections end up maintaining control. Usually, when ...

Should GLP-1 agonists be held during chemotherapy?

5
3 Answers

Mednet Member
Mednet Member
Endocrinology · Brigham And Womens Hospital Endocrinology

I think there are several aspects to this question. First, is there evidence that as a class GLP-1 RAs increase the risk of cancer or worsen prognosis during cancer? I could find nothing to raise concerns about outcomes. One recent report even showed a decreased risk of some cancers with GLP-1 RA co...

How do you assess and adjust treatment in patients who develops hypothyroidism after being on lithium for several years?

2
1 Answers

Mednet Member
Mednet Member
Psychiatry · University of Pittsburgh Medical Center

It depends on whether the patient is symptomatic. If not, careful monitoring is all that is needed. If there are significant symptoms, treatment with levothyroxine would be needed. Continued use of lithium is appropriate if it has been effective over time.

When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?

1
3 Answers

Mednet Member
Mednet Member
Endocrinology · Duke University Hospital

My practice has been that after 2-3 years of denosumab, I wait 6 months and then start zoledronic acid.

How often do you monitor pituitary adenomas once established as non-functioning?

2 Answers

Mednet Member
Mednet Member
Endocrinology · Johns Hopkins Endocrinology and Pituitary Center

That depends on the size and location (close to the chiasma?). Without pathology, which may help determine aggressiveness (mitotic rate, Ki67), it is impossible to predict the growth rate. For macros, I repeat an MRI in 6 months, and, if no change, I double the interval. For micros, there is recent ...

Do you recommend using anastrazole in men developing gynecomastia while on testosterone replacement treatment for hypogonadism depending on pre-treatment estradiol level?

1
1 Answers

Mednet Member
Mednet Member
Endocrinology · Endocrine Care Center At Uw Medical Center Roosevelt

There is no role for aromatase inhibitors (e.g., anastrozole) for the prevention of gynecomastia. A randomized trial of anastrozole for the treatment of gynecomastia demonstrated no benefit compared to placebo.There is no reason to administer prophylactic therapy prior to the initiation of testoster...

What factors would lead you to extend the duration of antithyroid drug therapy in a patient with Graves' disease who is clinically euthyroid at 12 months but has risk factors for recurrence?

2
3 Answers

Mednet Member
Mednet Member
Endocrinology · Johns Hopkins Outpatient Endocrinology

One should never discontinue methimazole after an arbitrary period of time without checking anti-TSH receptor antibody levels. If they are positive or even “normal” but not undetectable, the patient will inevitably have a recurrence of their hyperthyroidism relatively quickly (Laurberg et al., PMID ...

For hypothyroid patients on dual replacement therapy (levothyroxine & liothyronine), do you recommend monitoring TSH while holding off on the morning T3 dose?

2
3 Answers

Mednet Member
Mednet Member
Endocrinology · Johns Hopkins Outpatient Endocrinology

No, I do not withhold the morning dose of T3. Older studies have shown no effect of an oral dose of T3 on serum TSH levels (Saberi & Utiger, PMID 4422006).

Do you recommend initiating zoledronic acid for osteoporosis at the time of hospitalization for a fracture?

2
1 Answers

Mednet Member
Mednet Member
Endocrinology · Boston University School of Medicine

I did not institute bisphosphonate therapy during hospitalization for a fracture. It would have been helpful to have known bone remodeling markers if the patient had been followed for osteoporosis. It is reasonable to institute antiresorptive therapy in patients with high bone turnover. However, I d...

What other considerations for hyperlipidemia management would you have for a patient with multiple prior PCIs whose LDL remains above goal on high intensity statin, ezetimibe, and evolocumab, assuming the patient is compliant with medications?

3
3 Answers

Mednet Member
Mednet Member
Cardiology · Yale School of Medicine

There are a few options, most of which depend on insurance coverage and patient preferences. But first, would do a chart biopsy to assess the efficacy of each of the therapies to better understand the reason for persistent LDL elevation. Perhaps they have a dysfunctional LDL receptor, so upregulatio...